Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration

AIMS: To examine 12-month outcomes of eyes switching from intravitreal ranibizumab to aflibercept for neovascular age-related macular degeneration (nAMD). METHODS: Database observational study of eyes with nAMD tracked by the Fight Retinal Blindness outcome registry that received ranibizumab for at...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Ophthalmol
Autors principals: Barthelmes, Daniel, Campain, Anna, Nguyen, Phuc, Arnold, Jennifer J, McAllister, Ian L, Simpson, Judy M, Hunyor, Alex P, Guymer, Robyn, Essex, Rohan W, Morlet, Nigel, Gillies, Mark C
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2016
Matèries:
Clinical Science
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5256411/
https://ncbi.nlm.nih.gov/pubmed/26994110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bjophthalmol-2015-308090
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars